Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Ying Cui, Guihua Shen, Linlin Ma & Qiubo Lv. (2021) Overexpression of NDRG2 promotes the therapeutic effect of pazopanib on ovarian cancer. Journal of Receptors and Signal Transduction 41:6, pages 546-552.
Read now
Read now
Articles from other publishers (11)
Fine Aliyuda, Michele Moschetta, Aruni Ghose, Kathrine Sofia Rallis, Matin Sheriff, Elisabet Sanchez, Elie Rassy & Stergios Boussios. (2023) Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors. Current Cancer Drug Targets 23:6, pages 433-446.
Crossref
Crossref
Vipul Bhardwaj, Xi Zhang, Vijay Pandey & Manoj Garg. (2023) Neo-vascularization-based therapeutic perspectives in advanced ovarian cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1878:3, pages 188888.
Crossref
Crossref
Keqian Zhang, Wenwei Wang, Ting Zhang & Lan Liang. (2022) Efficacy and treatment-related adverse events of multi-targeted tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. International Journal of Clinical Pharmacy 44:6, pages 1232-1246.
Crossref
Crossref
Tianyu Qin & Gang Chen. (2022) Recent advances in targeted therapy for ovarian cancer. Oncology and Translational Medicine, pages 28-35.
Crossref
Crossref
Guido Bocci, Marta Banchi, Diana Gonzalez Garcia, Serina Batson & Giulio Francia. 2022. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy
127
146
.
Mathew Cowan, Wendy M. Swetzig, Valery Adorno-Cruz, Mario J. Pineda, Nikki L. Neubauer, Emily Berry, John R. Lurain, Shohreh Shahabi, Deanna Taiym, Valerie Nelson, Kaitlyn Lucrezia O'Shea, Masha Kocherginsky & Daniela Matei. (2021) Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial. Gynecologic Oncology 163:1, pages 57-63.
Crossref
Crossref
Yue Zhou, Mei He, Rui Li, Yuan Peng, Feng Li, Shengqian Li & Ming Yang. (2021) The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. BioMed Research International 2021, pages 1-10.
Crossref
Crossref
Nerethika Ravichandiran, Muneesh Kumar Barman, Sai Tejaswi Lavuri, Manjita Srivastava, Shalini Sakthivel, Meenakshi Singh, Kailash Chand, Subash C. Sonkar & Prudhvilal Bhukya. 2021. Handbook of Research on Advancements in Cancer Therapeutics. Handbook of Research on Advancements in Cancer Therapeutics
433
466
.
Seema Gulia, Jaya Ghosh, Jyoti Bajpai, Sushmita Rath, Amita Maheshwari, T.S. Shylasree, Kedar Deodhar, Meenakshi Thakur & Sudeep Gupta. (2020) Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer. JCO Global Oncology:6, pages 542-547.
Crossref
Crossref
Stefanie Avril, Yasemin Dincer, Katharina Malinowsky, Claudia Wolff, Sibylle Gündisch, Alexander Hapfelmeier, Melanie Boxberg, Holger Bronger, Karl-Friedrich Becker & Barbara Schmalfeldt. (2017) Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients. Oncotarget 8:58, pages 97851-97861.
Crossref
Crossref
Aneta Pogorzelska, Jarosław Sławiński, Beata Żołnowska, Krzysztof Szafrański, Anna Kawiak, Jarosław Chojnacki, Szymon Ulenberg, Joanna Zielińska & Tomasz Bączek. (2017) Novel 2-(2-alkylthiobenzenesulfonyl)-3-(phenylprop-2-ynylideneamino)guanidine derivatives as potent anticancer agents – Synthesis, molecular structure, QSAR studies and metabolic stability. European Journal of Medicinal Chemistry 138, pages 357-370.
Crossref
Crossref